Form EFFECT Quoin Pharmaceuticals
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 25, 2026 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EMA grants orphan drug status to Quoin's QRX003 for skin disorder
- Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
- Next Shiba Inu Alternative? Remittix Brings a $0.28 PayFi Entry as Bitcoin’s Next Big Rally Remains in Focus
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share